Tamoxifen — no longer a golden standard for adjuvant therapy in the treatment of premenopausal patients with hormone-sensitive breast cancer

Abstract

For several decades, in breast cancer patients with a luminal subtype, tamoxifen has been the main endocrine therapy in adjuvant setting in both pre-and postmenopausal women. However, it may be suboptimal in some premenopausal patients. The results of prospective, randomised studies SOFT/TEXT clearly demonstrated that the combination of OFS with TAM or IA is more effective than monotherapy TAM in breast cancer premenopausal women with hormonesensitive early breast cancer and a high risk of recurrence. NOWOTWORY J Oncol 2016; 66, 5: 415-417